(MedPage Today) — The FDA approved lenacapavir (Yeztugo) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents, Gilead Sciences announced on Wednesday.
An injectable HIV-1 capsid inhibitor…
Source link : https://www.medpagetoday.com/hivaids/hivaids/116154
Author :
Publish date : 2025-06-18 20:44:00
Copyright for syndicated content belongs to the linked Source.
